FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Seeks Injunction Against Steiner Biotechnology

[ Price : $8.95]

The Department of Justice seeks an injunction to stop Steiner Biotechnology from manufacturing and marketing adulterated and misbr...

FDA Questions Zynlontas Benefit/Risk: Report

[ Price : $8.95]

FDA is raising questions about the risk/benefit of ADC Therapeutics Zynlonta as a second-line treatment for diffuse large B-cell l...

3 Observations on Reliance Life Sciences FDA-483

[ Price : $8.95]

FDA releases the Form FDA-483 issued following an inspection at Indias Reliance Life Sciences drug manufacturing facility in Navi ...

PDUFA VIII Commitment Letter Outlines Changes to Drug Review, Manufacturing Oversight

[ Price : $8.95]

FDA releases the proposed recommendations for the eighth reauthorization of the Prescription Drug User Fee Act, outlining changes ...

Guidance on Risk-Based Approach to Drug Packaging Systems

[ Price : $8.95]

FDA issues a draft guidance proposing a risk-based framework for evaluating the container-closure systems used to package human dr...

Experts Warn of Edema Risk With Vykat XR as FDA Evaluates Risk

[ Price : $8.95]

Foundation for Prader-Willi Research warns that real-world reports of edema and other serious heart and respiratory problems among...

Accelerated Approval for Zenbexus Combo in Multiple Myeloma

[ Price : $8.95]

FDA grants Bristol-Myers Squibb accelerated approval for Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-f...

Ban Infants Tylenol: Childrens Health Defense

[ Price : $8.95]

Childrens Health Defense petitions FDA to ban Infants Tylenol and place Boxed Warnings on labeling for some other Tylenol products...

Use More Advisory Committee Temporary Voting Members: Column

[ Price : $8.95]

A Center for Medicine in the Public Interest opinion column calls on FDA to more aggressively recruit and use advisory committee t...

FDA Obstacles Lead to Overseas Trials: Survey

[ Price : $8.95]

A survey of 37 biotech executives shows FDA obstacles are sending more first-in-human trials overseas.